Literature DB >> 10699933

Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis.

H Lazar1, A Baltzer, C Gimmi, A Marti, R Jaggi.   

Abstract

The erbB-2/neu oncogene is frequently over-expressed in many different tumors in humans, including those of breast and ovary. The oncogene encodes a receptor tyrosine kinase closely related to the epidermal-growth-factor receptor. We studied effects on differentiation and cell death of erbB-2/neu during mammary-gland development in transgenic mice expressing an activated, oncogenic rat erbB-2/neu gene controlled by the mammary-gland-specific promoter from mouse-mammary-tumor virus (MMTV-LTR). Transgenic animals develop mammary cancer after repeated pregnancies and lactation. We present evidence that over-expression of erbB-2/neu in these mice is restricted to tumor cells. Tumor cells fail to differentiate and express milk proteins such as beta-casein and whey acidic protein (WAP) during lactation. Epithelial-cell apoptosis during normal involution is characterized by non-random DNA degradation into oligonucleosomal fragments. Tumor cells were mostly refractory to this developmentally controlled programmed cell death. Distinct areas within tumors, however, showed spontaneous cell death as measured by in situ TUNEL staining that co-localized with caspase-3-like activity. Our results indicate that the control of developmental cell death during involution is disturbed in erbB-2/neu-induced tumors although cell death and caspase activation can take place. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699933

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.

Authors:  Eva Gonzalez-Suarez; Daniel Branstetter; Allison Armstrong; Huyen Dinh; Hal Blumberg; William C Dougall
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

2.  Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue.

Authors:  Zhao-Shan Niu; Mei Wang
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

3.  Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis.

Authors:  Hexin Chen; Ji Shin Lee; Xiaohui Liang; Huiping Zhang; Tao Zhu; Zhe Zhang; M Evangeline Taylor; Cynthia Zahnow; Lionel Feigenbaum; Alan Rein; Saraswati Sukumar
Journal:  Cancer Res       Date:  2008-05-07       Impact factor: 12.701

4.  Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Shangqin Guo; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

5.  A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development.

Authors:  S Castillo-Lluva; L Hontecillas-Prieto; A Blanco-Gómez; M Del Mar Sáez-Freire; B García-Cenador; J García-Criado; M Pérez-Andrés; A Orfao; M Cañamero; J H Mao; T Gridley; A Castellanos-Martín; J Pérez-Losada
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

6.  Excessive milk production during breast-feeding prior to breast cancer diagnosis is associated with increased risk for early events.

Authors:  Emma Gustbée; Charlotte Anesten; Andrea Markkula; Maria Simonsson; Carsten Rose; Christian Ingvar; Helena Jernström
Journal:  Springerplus       Date:  2013-07-03

Review 7.  Mammary involution and breast cancer risk: transgenic models and clinical studies.

Authors:  Derek C Radisky; Lynn C Hartmann
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-04-30       Impact factor: 2.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.